Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Molecular Analysis for Therapy Choice MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase 2 Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Principal Investigator: Levine, Ellis G
A Registry of Complementary/Alternative Medicine (CAM) Services (Intended for Correlation with Pediatric Cancer and Non-Malignant Hematological Disorders Clinical Symptoms)
Principal Investigator: Kelly, Kara M
(KO-MEN-001) A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO 539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer," (NCT03199885)
Principal Investigator: Levine, Ellis G
Does increased mobility assessed with 3D motion tracking technology lead to early post-operative recovery among patients undergoing genitourinary surgeries
Principal Investigator: Guru, Khurshid
(S1900) A Master protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMap screening Study
Principal Investigator: Chen, Hongbin
EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
Principal Investigator: Singh, Anurag K
(COG ACNS1721) A Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High Grade Glioma (HGG) without H3K27M or BRAFV600E Mutations
Principal Investigator: Twist, Clare J
(S1801) A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma
Principal Investigator: Ernstoff, Marc S
Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center
Principal Investigator: Case, Amy A
A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
Principal Investigator: Fountzilas, Christos
(A041702) A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age)With Chronic Lymphocytic Leukemia
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not...
Principal Investigator: Hillengass, Jens
A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
(SWOG S1815) A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Principal Investigator: Iyer, Renuka V
Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) with Pembrolizumab, in Subjects Who Have Failed Cisplatin-based Chemotherapy with Locally Advanced (Unresectable) or Metastatic Transitional Cell Cancer (TCC) of the Urothelium
Principal Investigator: Chatta, Gurkamal S
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Principal Investigator: Chatta, Gurkamal S
A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors
Principal Investigator: Gandhi, Shipra
(ALKS 4230-001) A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Principal Investigator: Ernstoff, Marc S
(EDDOP NCI 10089) A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification...
Principal Investigator: McCarthy, Philip L
(ALTE16C1) Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Principal Investigator: Rokitka, Denise A
A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)
Principal Investigator: Iyer, Renuka V
(19244); REFINE: Regorafenib observational study in hepatocellular carcinoma
Principal Investigator: Iyer, Renuka V
(GMI-1271-301) A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Principal Investigator: Przespolewski, Amanda C
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
Principal Investigator: Dy, Grace K
(NRG-DT001) A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)
Principal Investigator: Kane, John M
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Principal Investigator: Chatta, Gurkamal S
Impact of a National Comprehensive Cancer Network Compliant Multidisciplinary Consortium on Treatment Decisions in Patients with Localized Prostate Cancer
Principal Investigator: Guru, Khurshid
Phase 1/1b Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS
Principal Investigator: Wang, Eunice S
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia ...
Principal Investigator: Wang, Eunice S
Comparing Unilateral and Bilateral Deep Inferior Epigastric Perforators (DIEP) Flaps for unilateral breast reconstruction
Principal Investigator: Moon, Wong K
(NRG-GY017) Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Principal Investigator: Lele, Shashikant B
(A171601) A PHASE II TRIAL ASSESSING THE TOLERABILITY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER
Principal Investigator: O'Connor, Tracey L
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma
Principal Investigator: Puzanov, Igor
Health Promotion in African American Cancer Survivors: Pilot Implementation Research (National Witness Project® Witness Role Models Use Precision Nutrition)
Principal Investigator: Devonish, Julia A
A novel parenting skills intervention to improve medication adherence in pediatric cancer
Principal Investigator: Bouchard, Elizabeth G
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors
Principal Investigator: Puzanov, Igor
Feasibility of Strength Training and Impact on Pain and Quality of Life in Patients with Multiple Myeloma
Principal Investigator: Hillengass, Jens
(S1712) A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
Principal Investigator: Thompson, J E
(S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Principal Investigator: Chatta, Gurkamal S
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects with Relapsed and/or Refractory B Cell Lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(CITN-14) Randomized Phase II study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma
Principal Investigator: Chatta, Gurkamal S
Enhancing a home-based walking intervention among breast cancer survivors with rTMS: Feasibility and limited efficacy testing
Principal Investigator: Sheffer, Christine E
(EA2165) A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Principal Investigator: Boland, Patrick M
(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Principal Investigator: Fung-Kee-Fung, Simon
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
Principal Investigator: Fountzilas, Christos
A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy
Principal Investigator: George, Saby
A Phase IB/2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumors
Principal Investigator: Fountzilas, Christos
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (POD1UM-102)
Principal Investigator: Fountzilas, Christos
A Phase II Study of Palbociclib (PD-0332991) in Combination with Ibrutinib in Patients with Previously Treated Mantle Cell Lymphoma
Principal Investigator: Torka, Pallawi
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With...
Principal Investigator: Dy, Grace K
Phase Ib/II Study of Enzalutamide with Venetoclax (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Principal Investigator: Chatta, Gurkamal S
A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer
Principal Investigator: Gandhi, Shipra
Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-induced Obese Frailty in Survivors of Advanced Prostate Cancer
Principal Investigator: Chatta, Gurkamal S
(A021602) RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON EVEROLIMUS (CABINET)
Principal Investigator: Iyer, Renuka V
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Principal Investigator: Fountzilas, Christos
(A061202) A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Principal Investigator: Hillengass, Jens
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability
Principal Investigator: Quisenberry, Amanda J
Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer
Principal Investigator: Yendamuri, Sai S
CONNECT (Clinical Outcomes of Nationwide, Naturalistic E-Cig Trial)
Principal Investigator: Goniewicz, Maciej L
(NCI 9673) Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Amendment)
Principal Investigator: Boland, Patrick M
Phase 2 Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Principal Investigator: Iyer, Renuka V
Effects of filter ventilation on sensory response, smoking topography, and inhalation (COMET 2 2.1)
Principal Investigator: O'Connor, Richard J
Aromatherapy: An Integrative Option for Symptom Management in Cancer Care
Principal Investigator: Rokitka, Denise A
Enhancing infrastructure for Native American and Rural Cancer Control Research Capacity at Roswell Park Comprehensive Cancer Center
Principal Investigator: Bouchard, Elizabeth G
(ACCL1633) The Effectiveness of Lactobacillus plantarum in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Principal Investigator: Bambach, Barbara J
(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Principal Investigator: Twist, Clare J
A Randomized, Multi-Center Phase 2 Trial with a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy versus SoC Therapy alone for the Treatment of Patients with Locally Advanced or...
Principal Investigator: Arshad, Hassan
A Single-center Phase I Dose Escalation/Response Trial to Evaluate the Safety, Tolerability, and Anti-tumor Efficacy of Intra-arterial CBL0137 for Patients with Advanced Extremity Melanoma or Sarcoma
Principal Investigator: Skitzki, Joseph J
Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation
Principal Investigator: Sheffer, Christine E
Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous "switching" between flavors (CRoFT_3.1)
Principal Investigator: Goniewicz, Maciej L
A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD 73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Principal Investigator: Puzanov, Igor
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Principal Investigator: Barth, Matthew J
Exercise and Nutrition Intervention in Older Breast Cancer Survivors
Principal Investigator: O'Connor, Tracey L
Effects of Physical Distraction and Music on Anxiety during Wide Local Excision
Principal Investigator: Schierer, Shirley
Phase II trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]
Principal Investigator: George, Saby
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases (Adjuvant Avelumab in MCC (ADAM) Trial
Principal Investigator: Ernstoff, Marc S
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Principal Investigator: Gandhi, Shipra
(CA-ALT-803-02-17) QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination with Pembrolizumab or Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer who have Disease Progression Following an Initial...
Principal Investigator: Yau, Edwin H
Understanding the relationship of caregiver stress to perceived preparedness for prescribed tasks and responsibilities caring for patients undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CS+HIPEC)
Principal Investigator: Stewart, Erika S
Photoacoustic Imaging of Human Breast
Principal Investigator: Bonaccio, Ermelinda
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Principal Investigator: Levine, Ellis G
(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Principal Investigator: Twist, Clare J
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors
Principal Investigator: Ernstoff, Marc S
(NRG-GY007) A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator: Lele, Shashikant B
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer
Principal Investigator: Gandhi, Shipra
Evaluation of Roswell Park Cessation Services
Principal Investigator: Sheffer, Christine E
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Principal Investigator: Chatta, Gurkamal S
Strengthening knowledge for future generations: Cancer bio-banks in the landscapes of the Haudenosaunee
Principal Investigator: Haring, Rodney C
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Principal Investigator: Dy, Grace K
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
Principal Investigator: Noyes, Ekaterina
Understanding health behaviors and perceptions of cancer in non-English speaking populations
Principal Investigator: Glaser, Kathryn M
(UTX-TGR-205) A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin¿s Lymphoma
Principal Investigator: Sundaram, Suchitra
A Phase 1b/2 Study of PCM-075 in Combination with either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML)
Principal Investigator: Wang, Eunice S
Phase 1 dose escalation, multi-tumor study to assess the safety, tolerability and antitumor activity of genetically engineered MAGE-A4c1032T in HLA-A2+ subjects with MAGE-A4 positive tumors (ADP-0044-001)
Principal Investigator: Odunsi, Adekunle O
(ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3...
Principal Investigator: Wang, Eunice S
General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial: Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia
Principal Investigator: Quinn, Timothy D
A Randomized, Open-Label Study to Assess the Pain, Toxicity and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated with Chemoradiation for Head and Neck Cancer
Principal Investigator: Singh, Anurag K
A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal Investigator: Wang, Eunice S
An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma
Principal Investigator: Lee, Kelvin
(ARO-021) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
First-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax-AXL-ADC) in patients with solid tumors
Principal Investigator: Dy, Grace K
Clinical Proteomics Tumor Analysis Consortium (CPTAC) Phase III Research Protocol
Principal Investigator: Foster, Barbara A
A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Principal Investigator: Wang, Eunice S
Effects of package color and descriptors on tobacco product perceptions (COMET 2 1.2)
Principal Investigator: O'Connor, Richard J
A Pilot Study of Photoacoustic Imaging (PAI)
Principal Investigator: Singh, Anurag K
(NSABP B-51) A Randomized Phase III Clinical Trial Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to...
Principal Investigator: Fung-Kee-Fung, Simon
(NRG-HN004) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Principal Investigator: Singh, Anurag K
RE-AIMing Nurses for Sleep Screening, Brief Intervention and Referral to Treatment (Sleep-SBIRT)
Principal Investigator: Dean, Grace E
(EA4151) A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Isolation of CD34 stem cells using the Miltenyi Biotec CliniMACS CD34 Reagent System as a humanitarian use device
Principal Investigator: Chen, George L
AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Principal Investigator: Twist, Clare J
A PHASE 1 DOSE ESCALATION STUDY OF DS-3032B, AN ORAL MDM2 INHIBITOR, AS SINGLE AGENT AND IN COMBINATION WITH 5-AZACITIDINE IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Principal Investigator: Wang, Eunice S
(A221504) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)
Principal Investigator: Chen, Hongbin
Opioid Use in Post-operative Gynecologic Oncology Patients
Principal Investigator: Zsiros, Emese
A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
Principal Investigator: George, Saby
(ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or...
Principal Investigator: Odunsi, Adekunle O
(ACCRU-GI-1617) MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
(SGN22E-002) A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer
Principal Investigator: George, Saby
(SWOG S1616) A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
Principal Investigator: Puzanov, Igor
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with MCL-1 Dependence ≥40%
Principal Investigator: Wang, Eunice S
A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Principal Investigator: Levine, Ellis G
The GYN Molecular Information Registry
Principal Investigator: Odunsi, Adekunle O
(A031501) Phase III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation
Principal Investigator: Levine, Ellis G
(A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch
Principal Investigator: Boland, Patrick M
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Principal Investigator: Grand'Maison, Anne C
(A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Principal Investigator: Wang, Eunice S
(ONO-7475-01) A Phase I open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias
Principal Investigator: Wang, Eunice S
(ALTE1631) A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia
Principal Investigator: Rokitka, Denise A
Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
Principal Investigator: Ernstoff, Marc S
(APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
Principal Investigator: Twist, Clare J
Electronic Cigarette Use During Pregnancy
Principal Investigator: Goniewicz, Maciej L
ALTE 15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Principal Investigator: Rokitka, Denise A
Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Principal Investigator: Lee, Kelvin
(APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Principal Investigator: Twist, Clare J
ACNS 1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Principal Investigator: Twist, Clare J
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Principal Investigator: Chatta, Gurkamal S
Validation of a mobile imaging system for oral cancer screening in low resource settings in India
Principal Investigator: Singh, Anurag K
(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Principal Investigator: Balderman, Sophia R
Phase 2A Study Evaluating a Chemokine-Modulatory Regimen in Patients with Colorectal Cancer Metastatic to the Liver
Principal Investigator: Boland, Patrick M
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anit-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with...
Principal Investigator: Dy, Grace K
(NRG-GY006) A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal...
Principal Investigator: Lele, Shashikant B
A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Principal Investigator: Gandhi, Shipra
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Principal Investigator: Wang, Eunice S
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator: Twist, Clare J
A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Principal Investigator: Wang, Eunice S
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Principal Investigator: Twist, Clare J
RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients
Principal Investigator: Hydeman, Jennifer A
The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency
Principal Investigator: Chen, George L
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
Principal Investigator: Iyer, Renuka V
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) given with Adjuvant Poly-ICLC in Conjunction with 5-Aza-2'deoxycytidine (Decitabine) and Nivolumab in Patients with MDS or Low Blast Count AML
Principal Investigator: Griffiths, Elizabeth A
An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women with Primary Nonrecurrent Breast Cancer Undergoing Surgery
Principal Investigator: Takabe, Kazuaki
CABL001A2301; A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
Principal Investigator: Thompson, J E
A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.
Principal Investigator: Balderman, Sophia R
Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer
Principal Investigator: Singh, Anurag K
A Multicenter Phase 2, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Principal Investigator: Puzanov, Igor
CA-ALT-803-01-16 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Principal Investigator: Guru, Khurshid
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial
Principal Investigator: Levine, Ellis G
IRONMAN: International Registry for Men with Advanced Prostate Cancer
Principal Investigator: Chatta, Gurkamal S
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Principal Investigator: George, Saby
IMCgp100-202, A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Principal Investigator: Puzanov, Igor
A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients
Principal Investigator: Singh, Anurag K
(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Impact of Menthol Delivery Methods on Smoker Sensory Perceptions
Principal Investigator: O'Connor, Richard J
Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection
Principal Investigator: Sumlin, Adam B
TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE
Principal Investigator: Odunsi, Adekunle O
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Principal Investigator: Levine, Ellis G
DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Principal Investigator: Kelly, Kara M
A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies
Principal Investigator: Odunsi, Adekunle O
AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line...
Principal Investigator: Kelly, Kara M
SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms
Principal Investigator: Wang, Eunice S
(NCI 9930) A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia
Principal Investigator: Kelly, Kara M
A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Odunsi, Adekunle O
(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Principal Investigator: Puzanov, Igor
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Principal Investigator: Ho, Christine M
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Principal Investigator: Iyer, Renuka V
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Principal Investigator: Mohler, James L
Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors: A Feasibility Pilot Trial
Principal Investigator: O'Connor, Tracey L
Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial)
Principal Investigator: Levine, Ellis G
BMT CTN 1502 Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)
Principal Investigator: Bambach, Barbara J
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Principal Investigator: Chatta, Gurkamal S
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Principal Investigator: George, Saby
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Principal Investigator: George, Saby
A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia
Principal Investigator: Chen, George L
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Principal Investigator: Levine, Ellis G
INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Principal Investigator: Twist, Clare J
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Principal Investigator: Zsiros, Emese
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for...
Principal Investigator: Wang, Eunice S
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ,and Non-Colorectal Cancers with HER2 Amplification
Principal Investigator: Levine, Ellis G
(S1512) A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Principal Investigator: Ernstoff, Marc S
(S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...
Principal Investigator: Levine, Ellis G
Study 16-214-02 (Combination): A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC...
Principal Investigator: Puzanov, Igor
A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers
Principal Investigator: Puzanov, Igor
(A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Asprin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Principal Investigator: Levine, Ellis G
Moral Distress in Nurses providing direct patient care on inpatient oncology units and outpatient clinics
Principal Investigator: Dean, Grace E
(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Principal Investigator: Twist, Clare J
A multinational, open-label, dose escalation Phase I Study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
Principal Investigator: Odunsi, Adekunle O
NRG-GYN 005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or...
Principal Investigator: Lele, Shashikant B
A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) with PDT versus Standard of Care Surgery for Patients with T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity
Principal Investigator: Arshad, Hassan
A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Principal Investigator: O'Connor, Tracey L
(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Principal Investigator: Ernstoff, Marc S
(COG ARST1431) A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk...
Principal Investigator: Twist, Clare J
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory Ovarian Cancer
Principal Investigator: Odunsi, Adekunle O
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Principal Investigator: Levine, Ellis G
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Therapy in Patients with Advanced NSCLC or Squamous Head and Neck Cancer
Principal Investigator: Dy, Grace K
Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)
Principal Investigator: Kukar, Moshim
A Phase I/II Evaluation of Olaparib in combination with Durvalumab and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a...
Principal Investigator: Odunsi, Adekunle O
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combinationwith Pembrolizumab in Subjects with Advanced Solid Tumors
Principal Investigator: Ernstoff, Marc S
(EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Principal Investigator: Dy, Grace K
(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Principal Investigator: Rokitka, Denise A
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Principal Investigator: Wang, Eunice S
(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Principal Investigator: Levine, Ellis G
(EAY 131-T MATCH): GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Principal Investigator: Levine, Ellis G
(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Principal Investigator: Levine, Ellis G
(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Principal Investigator: Levine, Ellis G
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Principal Investigator: Lee, Kelvin
(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Principal Investigator: Twist, Clare J
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas
Principal Investigator: Chowdhry, Varun K
(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide ...
Principal Investigator: Levine, Ellis G
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Principal Investigator: Levine, Ellis G
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies
Principal Investigator: Fountzilas, Christos
(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly...
Principal Investigator: Bambach, Barbara J
(COG AALL1331) Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Principal Investigator: Twist, Clare J
A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Chen, Hongbin
(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Principal Investigator: Twist, Clare J
(E4512 )A randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator: Chen, Hongbin
(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Dy, Grace K
(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator: Dy, Grace K
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies
Principal Investigator: Odunsi, Adekunle O
(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Principal Investigator: Wang, Eunice S
A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients at High Risk for Developing Lung Cancer with a Civilian Expansion
Principal Investigator: Reid, Mary E
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY...
Principal Investigator: Odunsi, Adekunle O
(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Principal Investigator: Rokitka, Denise A
Phase I/Ib Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
NY-ESO-1 Expression in Patients with Solid Tumors
Principal Investigator: Odunsi, Adekunle O
A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Principal Investigator: George, Saby
(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Principal Investigator: McCarthy, Philip L
Examining Quality of Life Among Long-Term Survivors of Childhood Cancer
Principal Investigator: Rokitka, Denise A
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors
Principal Investigator: McCarthy, Philip L
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer
Principal Investigator: Moysich, Kirsten B
(ALTE03N1/ CHOB 2519) Key Adverse Events Following Childhood Cancer
Principal Investigator: Rokitka, Denise A
Lung Bronchoscopy Research Samples & Database
Principal Investigator: Hennon, Mark W
Evaluation of Smoker Reactions to Novel Tobacco Products
Principal Investigator: Bansal Travers, Maansi
(COG ALTE05N1/ DB 2518) Umbrella Long-Term Follow-Up Protocol
Principal Investigator: Rokitka, Denise A
Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum
Principal Investigator: Hernandez-Ilizaliturri, Francisco J